Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 02 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Risk of recurrent H pylori infection after initial eradication

This  week's issue of the Journal of the American Medical Association investigates the risk of recurrent H pylori infection 1 year after initial eradication therapy in Latin American communities.

News image

The long-term effectiveness of Helicobacter pylori eradication programs for preventing gastric cancer will depend on recurrence risk and individual and community factors.

Dr Douglas Morgan and colleagues estimated the risk of H pylori recurrence and assess factors associated with successful eradication 1 year after treatment.

Cohort analysis of 1463 randomized trial participants aged 21 to 65 years from 7 Latin American communities, who were treated for H pylori and observed between 2009 and 2011.

Patients were randomized to 1 of 3 treatment groups, including 14-day lansoprazole, amoxicillin, and clarithromycin, 5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole, or 5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole.

The research team reported that participants with a positive C-urea breath test (UBT) 6 to 8 weeks posttreatment were offered voluntary re-treatment with 14-day bismuth-based quadruple therapy.

One year after treatment for H pylori infection, recurrence occurred in 12%
Journal of the American Medical Association

Recurrent infection after a negative posttreatment urea breath test and factors associated with successful eradication at 1-year follow-up.

The doctors noted that among participants with urea breath test-negative results who had a 1-year follow-up urea breath test, 125 tested urea breath test positive, a recurrence risk of 12%.

Recurrence was significantly associated with study site, nonadherence to initial therapy, and children in the household.

The researchers found that of the 281 with positive posttreatment urea breath test results, 138 completed re-treatment, of whom 93 tested urea breath test negative at 1 year.

Among the 1340 who had a 1-year urea breath test, 80%, 79%, and 78% had urea breath test-negative results in the triple, sequential, and concomitant groups, respectively, with 79% overall effectiveness.

In a single-treatment course analysis that ignored the effects of re-treatment, the percentage of urea breath test-negative results at 1 year was and was significantly associated with study site, adherence to initial therapy, male sex, and age.

The team of doctors reported that one-year effectiveness among all 1463 enrolled participants, considering all missing urea breath test results as positive, was 73%.

Dr Morgan's team concluded, "One year after treatment for H pylori infection, recurrence occurred in 12% of participants who had negative posttreatment urea breath test results."

"Recurrence determinants may be as important as specific antibiotic regimen in determining the long-term success of H pylori eradication interventions."

"Study findings are relevant to the feasibility of programs for the primary prevention of gastric cancer in high-incidence regions of Latin America."

JAMA 2013; 309(6): 578-586
15 February 2013

Go to top of page Email this page Email this page to a colleague

 01 July 2016 
Aspirin and colorectal cancer
 01 July 2016 
Outcome measures in celiac disease
 01 July 2016 
Growth factor activity and IBD
 30 June 2016 
Staging system for familial adenomatous polyposis
 30 June 2016 
Antibiotics in children and obesity
 30 June 2016 
IBS-type symptoms in pediatric IBD
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 29 June 2016 
Progression to esophageal carcinoma in Barrett's
 28 June 2016 
Gastric cancer screening in the USA
 28 June 2016 
Acute severe ulcerative colitis
 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
The Toronto Consensus for H. pylori treatment
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Touch screens in the IBD outpatient clinic
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Rectal cancer surgery checklist
 10 June 2016 
Breath as a marker for IBS
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Eosinophilic esophagitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us